Novartis stumbles in challenge to Missouri discounted drug mandate

An Eighth Circuit panel denied Novartis Pharmaceuticals' request to block Missouri's Senate Bill 751, which requires drugmakers to provide discounted 340B program drugs to eligible providers. The court ruled the law does not violate the dormant commerce clause as it regulates only in-state delivery of drugs to contract pharmacies.